St. Petersburg, FL – November 7, 2022 – Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that its phase 2 clinical trial of RSLV-132 in patients with long covid has been fully enrolled (NCT04944121).
St. Petersburg, FL–June 23, 2021–Resolve Therapeutics, pioneeringfirst–in–class,targeted, safetherapiesfor underserved autoimmune diseases, today announced that the US Food and Drug Administration has approved a New Investigational Drug application for RSLV–132 to initiate a phase 2 clinical trial in patients with long covid.
RSLV-132 Demonstrates Clinically Meaningful Improvement in Patients With Systemic Lupus Erythematosus in Phase 2a Clinical Trial
Resolve Therapeutics Publishes Positive Sjögren’s Syndrome Clinical Trial Results
Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus
Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome
Resolve Therapeutics To Present Phase II Data on Lead Product Candidate RSLV-132 at the 2019 EULAR European Congress of Rheumatology
Resolve Therapeutics Announces Publication of Clinical Data Demonstrating the Role of Circulating RNA in Systemic Lupus Erythematosus
Resolve to Present Data on Lupus Studies at International Rheumatology Conference
Resolve Announces Positive Clinical Data from RSLV-132 Lupus Study
Takeda and Resolve Therapeutics Enter Autoimmune Partnership
Resolve Therapeutics Raises $5.8 Million in Private Financing
How to Make Money in Biotech With No Hope of Going Public, Slim Odds of Getting Acquired
Resolve Announces Series A Financing, New Board Members
Resolve Nabs $2M For Lupus Drug, First Step on the Road to Returns With No IPO, No M&A